Literature DB >> 33718300

Conservative Management of Patent Ductus Arteriosus in Preterm Infants-A Systematic Review and Meta-Analyses Assessing Differences in Outcome Measures Between Randomized Controlled Trials and Cohort Studies.

Tim Hundscheid1, Esther J S Jansen1, Wes Onland2, Elisabeth M W Kooi3, Peter Andriessen4,5, Willem P de Boode1.   

Abstract

Objective: This study aims to evaluate outcome after conservative management (no pharmacological/surgical intervention other than fluid restriction, diuretics, or ventilator adjustments) compared with active (pharmacological and/or surgical) treatment for patent ductus arteriosus (PDA) in preterm infants and analyze differences in outcome between randomized controlled trials (RCTs) and cohort studies. Study Design: This is a systematic literature review using PubMed, EMBASE, and Cochrane library. RCTs and cohort studies comparing conservative management with active treatment were included. Meta-analysis was used to compare conservative management with any active (pharmacological and/or surgical), any pharmacological (non-prophylactic and prophylactic), and/or surgical treatment for mortality as primary and major neonatal morbidity as secondary outcome measure. Fixed-effect analysis was used, unless heterogeneity (I 2) was >50%. Outcome is presented as relative risk (RR) with 95% confidence interval.
Results: Twelve cohort studies and four RCTs were included, encompassing 41,804 and 720 patients, respectively. In cohort studies, conservative management for PDA was associated with a significantly higher risk for mortality (RR, 1.34 [1.12-1.62]) but a significantly lower risk for bronchopulmonary dysplasia (RR, 0.55 [0.46-0.65]), necrotizing enterocolitis (RR, 0.85 [0.77-0.93]), intraventricular hemorrhage (RR, 0.88 [0.83-0.95]), and retinopathy of prematurity (RR, 0.47 [0.28-0.79]) compared with any active PDA treatment. Meta-analysis of the RCTs revealed no significant differences in outcome between conservative management and active treatment.
Conclusion: No differences in mortality or morbidity for conservative management compared with active treatment regimens were observed in RCTs. Findings from cohort studies mainly highlight the lack of high-quality evidence for conservative management for PDA in preterm infants.
Copyright © 2021 Hundscheid, Jansen, Onland, Kooi, Andriessen and de Boode.

Entities:  

Keywords:  PDA; ibuprofen; indomethacin; ligation; morbidity; mortality; paracetamol; placebo

Year:  2021        PMID: 33718300      PMCID: PMC7946967          DOI: 10.3389/fped.2021.626261

Source DB:  PubMed          Journal:  Front Pediatr        ISSN: 2296-2360            Impact factor:   3.418


  38 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

2.  Spontaneous Closure of Patent Ductus Arteriosus in Infants ≤1500 g.

Authors:  Jana Semberova; Jan Sirc; Jan Miletin; Jachym Kucera; Ivan Berka; Sylva Sebkova; Sinead O'Sullivan; Orla Franklin; Zbynek Stranak
Journal:  Pediatrics       Date:  2017-07-12       Impact factor: 7.124

3.  Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches.

Authors:  Tetsuya Isayama; Lucia Mirea; Rintaro Mori; Satoshi Kusuda; Masanori Fujimura; Shoo K Lee; Prakesh S Shah
Journal:  Am J Perinatol       Date:  2015-03-31       Impact factor: 1.862

4.  Morbidities associated with patent ductus arteriosus in preterm infants. Nationwide cohort study.

Authors:  Pia Härkin; Riitta Marttila; Tytti Pokka; Timo Saarela; Mikko Hallman
Journal:  J Matern Fetal Neonatal Med       Date:  2017-07-11

5.  Neurodevelopmental Outcome at 2 Years of Age according to Patent Ductus Arteriosus Management in Very Preterm Infants.

Authors:  Laura Bourgoin; Cecile Cipierre; Quentin Hauet; Helene Basset; Veronique Gournay; Jean-Christophe Rozé; Cyril Flamant; Geraldine Gascoin
Journal:  Neonatology       Date:  2016-01-05       Impact factor: 4.035

6.  Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management.

Authors:  J M Brooks; J N Travadi; S K Patole; D A Doherty; K Simmer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05       Impact factor: 5.747

7.  Indomethacin prophylaxis for intraventricular hemorrhage in very low birth weight babies.

Authors:  P Arun Kumar Nair; Mangalore Govind Pai; Hesham Abdel Rahim Gazal; David Eustace Da Costa; Saleh Mohammed Al Khusaiby
Journal:  Indian Pediatr       Date:  2004-06       Impact factor: 1.411

8.  Paracetamol Accelerates Closure of the Ductus Arteriosus after Premature Birth: A Randomized Trial.

Authors:  Pia Härkin; Antti Härmä; Outi Aikio; Marita Valkama; Markku Leskinen; Timo Saarela; Mikko Hallman
Journal:  J Pediatr       Date:  2016-05-20       Impact factor: 4.406

Review 9.  Application of NPE in the assessment of a patent ductus arteriosus.

Authors:  David van Laere; Bart van Overmeire; Samir Gupta; Afif El-Khuffash; Marilena Savoia; Patrick J McNamara; Christoph E Schwarz; Willem P de Boode
Journal:  Pediatr Res       Date:  2018-07       Impact factor: 3.756

10.  Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial.

Authors:  Se In Sung; Myung Hee Lee; So Yoon Ahn; Yun Sil Chang; Won Soon Park
Journal:  JAMA Pediatr       Date:  2020-08-01       Impact factor: 16.193

View more
  2 in total

Review 1.  The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants.

Authors:  Sarah Dudley; Shawn Sen; Alison Hanson; Afif El Khuffash; Philip T Levy
Journal:  J Perinatol       Date:  2022-07-15       Impact factor: 3.225

2.  Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity.

Authors:  Tim Hundscheid; Afif El-Khuffash; Patrick J McNamara; Willem P de Boode
Journal:  Eur J Pediatr       Date:  2022-03-19       Impact factor: 3.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.